The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Texas MPN Workshop 2022 | Using CHIP to encourage early intervention in disease
Rafael Bejar, MD, PhD, University of California San Diego, San Diego, CA, explains the importance of early intervention in myeloproliferative neoplasms (MPNs), and further highlights the value of identifying clonal hematopoiesis of indeterminate potential (CHIP) and other mutations, and informing patients on the risks associated with these. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
Disclosures
Aptose Biosciences – employment and equity
Gilead – data safety monitoring committees chair
Epizyme – data safety monitoring committee chair
BMS – ad hoc advisory board honoraria, research funding
Takeda – research funding
